Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Biophytis SA ( (FR:ALBPS) ) has shared an announcement.
Biophytis SA has secured a non-dilutive bond financing line of up to €1 million from Hexagon Capital Fund to support its ongoing operations, particularly the clinical development of its OBA101 program. This financing strengthens the company’s cash position, enabling it to meet its financial needs through the first quarter of 2026. The bonds, issued with a nominal value of €1,000, will mature 24 months after issuance and bear an annual interest rate of 12%. The transaction allows Biophytis to continue focusing on its core development programs without diluting shareholder equity, although converting bonds into shares could slightly impact shareholder ownership percentages.
More about Biophytis SA
Biophytis SA is a clinical-stage biotechnology company focused on developing drug candidates for age-related diseases, including muscular diseases like sarcopenia and metabolic disorders such as obesity. The company is headquartered in Paris, France, with subsidiaries in Cambridge, Massachusetts, USA, and Brazil. Its shares are listed on Euronext Growth Paris and the OTC market.
Average Trading Volume: 299,190
Technical Sentiment Signal: Sell
Current Market Cap: €4.57M
Find detailed analytics on ALBPS stock on TipRanks’ Stock Analysis page.